Kornimate/medical-research-clean huggingface dataset:
visual quality and performance of eyes with asqelio™ edof toric lenses

Conditions: Cataract; Presbyopia Correction

Summary: this study evaluates the optical quality and clinical performance of the asqelio™ edof toric intraocular lens (iol) in patients undergoing cataract surgery or refractive lensectomy. the asqelio™ edof toric iol aims to provide improved vision at various distances and correct astigmatism compared to monofocal iols. postoperative outcomes, including visual clarity, refractive correction, and patient satisfaction, will be assessed three months after surgery.

cataract surgery is one of the most common procedures worldwide, typically involving the replacement of the cloudy natural lens with an intraocular lens (iol). traditional monofocal iols correct vision for a single distance but do not address intermediate or near vision, leading to dependence on glasses. the asqelio™ edof toric iol is designed to provide extended depth of focus, smoother transitions across distances, and astigmatism correction, potentially enhancing overall visual quality and reducing the need for glasses. this study compares the optical performance and patient outcomes of the asqelio™ edof toric iol with those of monofocal iols. key measures include optical quality, visual acuity at multiple distances, refractive correction, and patient-reported satisfaction. results will be collected during a three-month postoperative follow-up. the findings aim to inform the effectiveness of the asqelio™ edof toric iol in improving visual outcomes and quality of life for patients.

Eligibility criteria:
inclusion criteria: * patients aged 50 years or older who have undergone cataract surgery with phacoemulsification or refractive lensectomy, with bilateral implantation of the asqelio edof toric iol model etlio130c/etpio130c with a cylinder value of 0.0 d, or the spherical monofocal j\&j tecnis 1-piece iol model zcb00. * patients who have signed the informed consent form. * clear intraocular media, except for the presence of cataracts in both eyes prior to surgery. * postoperative potential visual acuity of 20/25 or better exclusion criteria: * preoperative corneal astigmatism greater than 1.00d. * patients who do not provide informed consent. * patients who do not understand the study procedure. * previous corneal surgery or trauma. * irregular cornea (e.g., keratoconus). * choroidal hemorrhage. * microphthalmos. * severe corneal dystrophy. * uncontrolled or medically controlled glaucoma. * clinically significant macular changes. * severe concomitant ocular disease. * cataract unrelated to aging. * severe optic nerve atrophy. * diabetic retinopathy. * proliferative diabetic retinopathy. * amblyopia. * extremely shallow anterior chamber. * severe chronic uveitis. * pregnant or breastfeeding. * rubella. * mature/dense cataract preventing preoperative fundus examination. * previous retinal detachment. * concurrent participation in another drug or clinical device investigation. * expectation of needing another ocular surgery during the study period

Keywords: intraocular lens extended depth-of-focus cataract surgery optical quality
chablis-sc1: a study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administered in addition to standard therapy in subjects with active systemic lupus erythematosus (sle) disease as defined by selena-sledai score ≥10 despite on-going stable corticosteroid therapy.


Eligibility criteria:
inclusion criteria: * fulfill at least 4 diagnostic criteria for sle defined by american college of rheumatology * positive antinuclear antibodies (ana) and/or anti-double stranded dna (anti-dsdna) * active sle disease as defined by selena-sledai score ≥10 despite on-going stable corticosteroid therapy * 18 years of age or older exclusion criteria: * severe active vasculitis, active central nervous system lupus, active lupus nephritis, uncontrolled hypertension or poorly controlled diabetes * malignancy within past 5 years * known to be positive for hiv and/or positive at the screening visit for hepatitis b, or hepatitis c * liver disease * anemia, neutropenia, or thrombocytopenia * active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections * history of active tuberculosis or a history of tuberculosis infection * pregnant or nursing

Keywords: sle lupus lupus erythematosus, systemic autoimmune diseases a-623 blisibimod
activity and balanced eating to reduce comorbidities and symptoms of ms

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is the leading cause of irreversible neurological disability among young women and the second leading cause of disability among young men in the u.s. cardiometabolic risk factors including obesity and hyperlipidemia are common among people with ms, and these risk factors are associated with severity and frequency of ms relapses and disease progression. people with ms often experience symptoms of pain, fatigue, and depression, which make adhering to a healthy lifestyle difficult, as evidenced by the high rates of unhealthy behaviors including poor diet and physical inactivity among this group. physical activity has reduced symptoms of ms and improved metabolic risk profiles, but little research has focused on the role of a dietary intervention combined with physical activity in this group. therefore, the purpose of this study is to test the efficacy of a combined diet and physical activity intervention for reducing cardiometabolic risks and ms symptoms when compared to a physical activity intervention alone.


Eligibility criteria:
inclusion criteria: * relapsing-remitting ms * on disease modifying treatment for 6 months * no relapse within the previous 30 days * bmi 25-55 kg/m2 * self-identify as not currently meeting recommendations for healthy diet and physical activity * ambulatory with or without assistance * reliable access to the internet via computer or smartphone * responsible for their personal food preparation or have input into the food prepared for them * score indicating low cognitive functioning on the telephone interview for cognitive status assessment exclusion criteria: * physician does not approve participation * use of the following diabetes medications: acetohexamide, chlorpropamide (diabinese), tolbutamide (orinase, tol-tab), tolazamide (tolinase), glipizide (glucotrol, glucotrol xl, metaglip), glyburide (micronase, diabeta, glynase, glucovance), glimepiride (amaryl), humalog or lispro, novolog or aspart, apidra or glulisine, regular (r) humulin or novolin, velosulin (for use in the insulin pump), nph (n), lente (l), ultralente (u), lantus, levemir or detemir, humulin 70/30, novolin 70/30, novolog 70/30, humulin 50/50, or humalog mix 75/25 * already on a specific diet meant to improve health * heart attack, stroke, or heart bypass surgery less than 6 months ago * pulmonary disease, cardiovascular disease or renal failure less than 6 months ago * smoking * cancer, hiv or liver/kidney disease * inability to travel to lakeshore for testing
the efficacy and safety of iguratimod (igu) in the treatment of primary sjögren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: a multi-center, prospective, open-label, randomized controlled study of efficacy and safety of iguratimod in patients with primary sjögren's syndrome


Eligibility criteria:
inclusion criteria: * diagnosed with pss by meeting the 2016 acr/eular classification criteria. * the patient complained of dry mouth and eyes. * positive anti-ssa/ro-60 antibody at screening. * igg≥16 g/l. * no hormone, immunosuppressant, biological agents or other treatments were received within 4 weeks before screening; * pregnancy test of is negative. use effective contraceptives during the trial (female) * those who did not participate in any drug trial within 12 weeks before enrollment exclusion criteria: * pregnant or lactating or planning to get pregnant during the duration of the study. * complicated with other ctd * complicated with malignancy * mental illness, a history of alcohol abuse, immunodeficiency, uncontrolled infections, and drug or other substance abuse * serious systemic damage, glucocorticoids, other immunosuppressants and biological agents should be added to control the condition: heart, liver (transaminase/bilirubin \>1.5 times the upper normal limit), kidney (cr≥133mmol/l), lung (fvc % \< 60%), blood (white blood cell \<3×109/l, hgb\<80g/l, plt\<80×109/l), etc. * fundus/visual field lesions; * allergic to any component of the study drug (igu and/or hcq); * the investigator considers the patient to be unsuitable for entry into the study

Keywords: primary sjögren's syndrome sjögren's syndrome iguratimod
the effectiveness of combined design nance/transpalatal arch appliance in maintaining arch dimensions after premature extraction of primary molars

Conditions: Space Maintenance

Summary: this study will evaluate the effectiveness of n-tpa appliance compared to nance sm in maintaining the arch dimensions after bilateral premature extraction of primary molars in children.

in this randomized controlled clinical trial, 30 healthy children, 8-9 years of age with premature extraction of bilateral maxillary primary molars will be selected. children will be randomly allocated into two equal groups of 15 children each according to the type of the appliance that will be used. group i will receive a a nance sm, and group ii a combined n-tpa appliance . panoramic x-rays and study casts will be made, and baseline measurements will be recorded including arch circumference, intermolar width and arch depth. the appliances will be fabricated and cemented intra-orally. the patients will be followed up at 3, 6 and 9 months for re-evaluation of arch circumference, intermolar width, arch depth, and patient acceptance.

Eligibility criteria:
inclusion criteria: * fully erupted maxillary permanent first molars. * angle's class i occlusion.(31) * adequate space for premolar eruption according to moyer's arch length analysis.(31) * fair to good oral hygiene according to silness and loe plaque index.(32) * no history of allergy to polymethyl methacrylate. exclusion criteria: * children with congenitally absent permanent successors. * children with successors not covered by bone with 2/3 of the root formed.(33)

Keywords: nance/transpalatal arch nance space maintainer space maintainer space maintenance
lateral rectus muscle tendon elongation

Conditions: Surgical Procedure, Unspecified; Ocular Discomfort; Strabismus, Divergent

Summary: to evaluate a technique using resected medial rectus muscle transplantation for elongation of lateral rectus tendon as a monocular surgery for large angle sensory exotropia.

a prospective study done in tanta university in the period between january 2017 and june 2018.it included 16 patients with sensory exotropia ≥50pd. full history was taken. visual acuity, cycloplegic refraction and fundus exam of both eyes was performed prior to surgery. strabismus angles were measured at near and distance by alternate prism cover test. any limitation of adduction or abduction was scaled from -4 to 0. patients were followed for 6 months. surgical procedure: the mr muscle was dissected through a limbal incision. two single arm 6-0 vicryl sutures were placed at desired distance from the insertion as the routine resection of rectus muscle and another pair of 6-0 vicryl was placed at the insertion. the muscle was then incised from its insertion, and the posteriorly (distally) placed 6-0 vicryl sutures were passed through the original insertion. the resected segment is then put in saline. a vicryl 6-0 suture was tied at the lr muscle insertion. the muscle was incised from its insertion. next, the stump of the resected segment was then sutured to the sclera at the desired position measured by the strabismus caliber according to the surgical dosage sufficient to correct the premeasured distant angle (taking into consideration the length of the added segment, which will be added to the amount of recession), and the distal end of this stump was sutured with the proximal end of lr with the 6-0 vicryl already placed on the lr. now the elongated muscle was sutured at desired site from the original insertion of lr as done in routine rectus muscle recession. the patients were followed at 1day after surgery, 2 weeks, 3 month, and 6 months. in each visit the distant angle of deviation was measured by prism cover test, any limitation of adduction and abduction was scaled, and patient satisfaction with results at last follow up was obtained, all results were recorded and tabulated.

Eligibility criteria:
inclusion criteria: * patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50pd. exclusion criteria: * patients with exotropia other than sensory type (alternating exotropia, intermittent exotropia) * angle of deviation less than 50 pd. * visual acuity more than 0.2 decimal in affected eye . * a or v pattern exotropia. * nystagmus . * refusal of surgery by the adult patients or caregiver of children.

Keywords: sensory exotropia lateral rectus elongation autograft
dexmedetomidine infusion in either total intravenous anesthesia or inhalational anesthesia to improve surgical field visibility in endoscopic sinus surgery

Conditions: Rhinosinusitis

Summary: dexmedetomidine infusion in either total intravenous anesthesia or inhalational anesthesia to improve surgical field visibility in endoscopic sinus surgery


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) class i and ii patients undergoing endoscopic sinus surgery in the age group from 18-50 years. exclusion criteria: * history of allergy to medications used in the study, refusal of patients to participate, hepatic or renal dysfunction, chronic pain condition, psychological and neurological disorders

Keywords: endoscopic sinus surgery , dexmedetomidine, surgical field visibility
a study to evaluate the efficacy and safety of ruxolitinib cream in participants with lichen sclerosus

Conditions: Lichen Sclerosus

Summary: the purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with lichen sclerosus. this is randomized, double-blind, vehicle-controlled (dbvc) study with a dbvc period of 12 weeks followed by an open label period (ole) period of 12 weeks.


Eligibility criteria:
inclusion criteria: * biopsy-proven ls in the anogenital area. * baseline iga score ≥ 2 for ls. * baseline itch nrs score ≥ 4 in anogenital area. * willingness to avoid pregnancy. exclusion criteria: * participants who do not have ls involving anogenital area. * concurrent conditions and history of other diseases: 1. are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including: candidiasis, chlamydia trachomatis, trichomonas vaginalis, neisseria gonorrhoeae, bacterial vaginosis, or herpes simplex. 2. have active genital/vulvar lesions at screening and day 1, not related to ls 3. chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline. * laboratory values outside of the protocol-defined criteria * pregnant or lactating participants or those considering pregnancy during the period of their study participation.. * other exclusion criteria may apply.

Keywords: lichen sclerosus skin diseases 18424 ruxolitinib topical cream vulvar disease
a1 versus a2® milk on the gastrointestinal physiology, symptoms and cognitive behaviour for the preschool children

Conditions: Gut Inflammation

Summary: this is a multiple-sites, double-blinded, randomized, controlled, parallel-designed, cross-over study among healthy preschoolers with 5 days consumption of a2 or a1 milk to compare the effects on gut inflammation, gastrointestinal symptoms and behavioral well-being.

gut inflammation is reflected by serum c-reactive protein (crp), hemoglobin (hb), interleukin-4 (il-4), immunoglobulin g (igg), immunoglobulin e (ige), immunoglobulin g1 (igg1), immunoglobulin g2a (igg2a), β-casomorphin-7 (bcm-7), glutathione, calcium (ca), iron (fe) and zinc (zn) concentration; gastrointestinal (gi) symptoms are measured via visual analog scale (vas) for gut tolerance, including borborygmus, bloating, break wind, abdominal pain, and diarrhea; behavioral well-being is assessed using subtle cognitive impairment test (scit). the total duration of study was 24 weeks, including subject enrollment, study intervention, laboratory testing, and providing clinical study report. the cross-over study consisted of 5 days of each product intervention; 10 days of wash-out in phase 1 and phase 2, respectively; and then followed by 6 weeks of statistical analysis and clinical report completion.

Eligibility criteria:
inclusion criteria: * non-regular milk drinker; * suffered from mild to moderate milk intolerance; * agree not to take any medication, supplements, nutrition or other dairy products including acidophilus milk; * parent(s) or legal guardian's consent to the study and willing to comply with study procedures; * parent(s) or guardian of infant agrees not to enroll infant another clinical study while participating in this study; * fully understand the nature, objective, benefit and the potential risks and side effects of the study. exclusion criteria: * have known dairy allergy; * suffered from severe milk intolerance; * unable to give written informed consent; * use of antibiotics at the time of screening, or during the past two weeks; * have history of fecal impaction; * trying to lose weight by following a diet or exercise regimen designed for weight loss, or taking any drug influencing appetite and any drug for weight loss for the last three months; * have participated in similar dairy or probiotics-containing product's clinical trials within 3 months before the screening; * currently taking medicines for cardiovascular or metabolic disease; * have history of or be diagnosed of any of the following diseases that may affect the study results: gastrointestinal disorders, hepatopathy, nephropathy, endocrine disease, blood disorders, respiratory and cardiovascular diseases; * currently suffering from any gastrointestinal disorders or gastrointestinal disease , including but not limited to: irritable bowel syndrome, colitis, ulcerative colitis, celiac disease, irritable bowel syndrome (ibs); * had hospitalizations within 3 months before screening; * according to investigator's judgment, current frequent users of drugs may affect the gastrointestinal function or immune system.
effectiveness and safety of physical exercises in the improvement of the sleep quality. regarding rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: physical exercise programs are effective and safe for the improvement of the sleep efficiency in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: • women ages 35-65 years diagnosed with rheumatoid arthritis according with the american college of rheumatology (acr) and european league against rheumatism (eular)criteria; pittsburgh sleep quality index ≥ 5; electrocardiogram test (ecg) at rest and at regular effort. exclusion criteria: * patients with joint restrictions due to disease. * other rheumatoid-associated diseases (fibromyalgia) with the exception of osteoarthritis of low degree. * those who are uncontrollably hypertense, diabetic, with thyroidopathy and cardiorespiratory diseases which stop them from practicing exercises. * class ii obesity (imc ≥ 35 kg/m2). * cognitive deficits. * depression. * patients not following the study rules such as exercise hours and / or time for the proposed program. * current physical exercise practitioner. * those undergoing medication treatment which would interfere sleep. * night shift workers who disrespect regular working schedule.

Keywords: rheumatoid arthritis sleep disorders polysomnography sleep stages physical exercise
correlation of hepatitis c, alcoholic liver disease, and renal failure with hyperfibrinolysis in liver failure

Conditions: Cirrhosis

Summary: 1. further characterize the incidence of hyperfibrinolysis in cirrhotics 2. correlate hyperfibrinolysis with 1. hepatitis c 2. alcoholic liver disease 3. the subset of a\&b with renal failure with and without dialysis 3. better describe the hyperfibrinolytic rotem profile in cirrhotics


Eligibility criteria:
inclusion criteria: * be on the the liver transplant waiting list exclusion criteria: * liver failure without eligibility for transplant

Keywords: fibrinolysis liver transplant thromboelastometry
incidence of post-operative pain after single-visit versus two-visit treatment

Conditions: Post-operative Pain

Summary: aim :to compare incidence of post-operative pain and apical healing after single-visit versus two-visit root canal treatment of teeth with necrotic pulp and apical periodontitis.

aim to compare incidence of post-operative pain and apical healing after single-visit versus two-visit root canal treatment of teeth with necrotic pulp and apical periodontitis. methodology: all teeth of the one and two-visit group were asymptomatic (92) and symptomatic (18) with a diagnosis of pulp necrosis (rct cases) determined by hot and cold sensitivity tests and radiographically all teeth showed a small and irregular radiolucency at the tooth apex. working length was established with eal and confirmed radiographically. reciprocating files (vdw, munich germany) were used to complete root canal preparation. edta served as a lubricant.

Eligibility criteria:
inclusion criteria: 1. the aims and requirements of the study were freely accepted; 2. treatment was limited to patients in good health; 3. all teeth had nonvital pulps and apical periodontitis, with or without a sinus tract; 4. a negative response to hot and cold pulp sensitivity tests; 5. presence of sufficient coronal tooth structure for rubber dam isolation; 6. no prior endodontic treatment on the involved tooth 7. no analgesics or antibiotics were used five days before the clinical procedures began. exclusion criteria: 1. patients who did not meet inclusion requirements; 2. patients who did not provide authorization for participation; 3. patients who were younger than 16 years old; 4. patients who were pregnant; 5. patients who were diabetic; 6. patients with a positive history of antibiotic use within the past month; 7. patients whose tooth had been previously accessed or endodontically treated; 8. teeth with root resorption, 9. immature/open apex, or a root canal in which patency of the apical foramen could not be established were all excluded from the study. teeth with periodontal pockets deeper than 4 mm also were excluded of the study.

Keywords: pain, one-visit two visits